炎症性肠病中苯二氮䓬类药物与Z药物的使用情况
基于加拿大曼尼托巴省行政数据,纳入5,741例新发炎症性肠病(IBD)患者并按1:5匹配对照,评估1997至2017年苯二氮䓬类及Z药物(合称BZD)使用率及与情绪/焦虑障碍的关联。2016年IBD队列苯二氮䓬类标化使用率为28.06/1000(95%CI 26.41-29.81),对照组为16.83/1000(95%CI 16.28-17.39),调整率比1.69(95%CI 1.56-1.79);Z药物标化使用率IBD队列为21.07/1000(95%CI 19.69-22.41),为对照组的1.87倍(95%CI 1.73-2.01)。2017年约20%的IBD患者使用苯二氮䓬类,20%使用Z药物。
要点
- 2016年IBD队列苯二氮䓬类标化使用率28.06/1000,对照组16.83/1000,调整率比1.69(95%CI 1.56-1.79)。
- IBD队列Z药物标化使用率为对照组的1.87倍(95%CI 1.73-2.01)。
- 2017年约20%的IBD患者使用苯二氮䓬类,20%使用Z药物。
核心结论
- IBD患者中BZD的使用比无IBD的人群对照更常见。
- 需要采取策略减少IBD患者中BZD的使用,并为情绪/焦虑障碍、睡眠障碍及其他症状性问题提供替代管理策略。
研究设计与样本
- 利用加拿大曼尼托巴省行政数据,识别5,741例新发IBD患者,并按性别、出生年份和地区以1:5比例匹配对照。
- 使用经验证的病例定义识别情绪/焦虑障碍,识别BZD配药记录。
- 采用多变量广义线性模型评估IBD、情绪/焦虑障碍与BZD使用之间的关联,时间范围为1997至2017年。
主要发现
- 2016年,年龄/性别标化苯二氮䓬类使用率每1,000人为:IBD队列28.06(95%CI 26.41-29.81),对照组16.83(95%CI 16.28-17.39),调整率比=1.69(95%CI 1.56-1.79)。
- IBD女性苯二氮䓬类发病率高于男性,但男女之间病例与对照的率比相似。
- 2016年,年龄/性别标化Z药物使用率每1,000人在IBD队列为21.07(95%CI 19.69-22.41),为对照组的1.87倍(95%CI 1.73-2.01)。
- 2017年,约20%的IBD患者使用苯二氮䓬类,20%使用Z药物。
- 调整协变量后,IBD与情绪/焦虑障碍对苯二氮䓬类和Z药物使用存在亚相加效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We estimated the incidence and prevalence of benzodiazepine and Z-drug (separately and jointly as BZD) use in the inflammatory bowel disease (IBD) population compared with matched controls without IBD and examined the association of mood/anxiety disorders (M/ADs) with the use of BZD from 1997 to 2017. METHODS: Using administrative data from Manitoba, Canada, we identified 5,741 persons with incident IBD who were matched in a 1:5 ratio to controls on sex, birth year, and region. Validated case definitions were used to identify M/AD. Dispensations of BZD were identified. Multivariable generalized linear models were used to assess the association between IBD, M/AD, and BZD use. RESULTS: In 2016, the incident age/sex-standardized benzodiazepine use rates per 1,000 were 28.06 (95% confidence interval [CI] 26.41-29.81) in the IBD cohort and 16.83 (95% CI 16.28-17.39) in controls (adjusted rate ratio = 1.69 [95% CI 1.56-1.79]). Benzodiazepine incidence rates were higher for women with IBD than men, but the RR between cases and controls were similar for men and women. The incident age/sex-standardized Z-drug use rate per 1,000 was 21.07 (95% CI 19.69-22.41) in the IBD cohort. This was 1.87-fold higher than in controls (95% CI 1.73-2.01). In 2017, approximately 20% of persons with IBD used benzodiazepines and 20% used Z-drugs. There was a subadditive effect of both benzodiazepine and Z-drug uses between IBD and M/AD after adjusting for covariates. DISCUSSION: The use of BZD is more common in people with IBD than in population controls. Strategies to reduce the use of BZDs in persons with IBD and to offer alternative management strategies for M/ADs, sleep disorders, and other symptomatic concerns are needed.
引用
- Bernstein CN, Fisk JD, Walld R, et al. Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease. Am J Gastroenterol. 2022. PMID: 36288107. doi:10.14309/ajg.0000000000001955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。